239 related articles for article (PubMed ID: 31356278)
1. Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).
Karoui M; Rullier A; Piessen G; Legoux JL; Barbier E; De Chaisemartin C; Lecaille C; Bouche O; Ammarguellat H; Brunetti F; Prudhomme M; Regimbeau JM; Glehen O; Lievre A; Portier G; Hartwig J; Goujon G; Romain B; Lepage C; Taieb J;
Ann Surg; 2020 Apr; 271(4):637-645. PubMed ID: 31356278
[TBL] [Abstract][Full Text] [Related]
2. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial.
Karoui M; Gallois C; Piessen G; Legoux JL; Barbier E; De Chaisemartin C; Lecaille C; Bouche O; Ammarguellat H; Brunetti F; Prudhomme M; Regimbeau JM; Glehen O; Lievre A; Portier G; Hartwig J; Goujon G; Romain B; Lepage C; Taieb J;
Colorectal Dis; 2021 Jun; 23(6):1357-1369. PubMed ID: 33580623
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial.
Karoui M; Rullier A; Luciani A; Bonnetain F; Auriault ML; Sarran A; Monges G; Trillaud H; Le Malicot K; Leroy K; Sobhani I; Bardier A; Moreau M; Brindel I; Seitz JF; Taieb J
BMC Cancer; 2015 Jul; 15():511. PubMed ID: 26156156
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
5. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
7. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.
Lim SH; Shim YM; Park SH; Kim HK; Choi YS; Ahn MJ; Park K; Zo JI; Sun JM
Cancer Res Treat; 2017 Jul; 49(3):816-823. PubMed ID: 27857024
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
Foxtrot Collaborative Group
Lancet Oncol; 2012 Nov; 13(11):1152-60. PubMed ID: 23017669
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.
Matsumura M; Hasegawa K; Oba M; Yamaguchi K; Uetake H; Yoshino T; Morita S; Takahashi K; Unno M; Shimada Y; Muro K; Matsuhashi N; Mori M; Baba H; Shimada M; Mise Y; Kawaguchi Y; Kagimura T; Ishigure K; Saiura A; Sugihara K; Kokudo N
Langenbecks Arch Surg; 2022 Jun; 407(4):1345-1356. PubMed ID: 35211831
[TBL] [Abstract][Full Text] [Related]
12. Clinical Evaluation of Preoperative Radiotherapy Combined with FOLFOX Chemotherapy on Patients with Locally Advanced Colon Cancer.
Zhou J; Guo Z; Yu W; Li S; Qiao W
Am Surg; 2019 Apr; 85(4):313-320. PubMed ID: 31043188
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
14. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
[TBL] [Abstract][Full Text] [Related]
15. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
[TBL] [Abstract][Full Text] [Related]
16. Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.
Mary F; Zaanan A; Boige V; Artru P; Samalin E; Coriat R; Bachet JB; Boubaya M; Benallaoua M; Tougeron D; Afchain P; Locher C; Baumgaertner I; Lecaille C; des Guetz G; Aparicio T;
Dig Liver Dis; 2016 Dec; 48(12):1498-1502. PubMed ID: 27623185
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
[TBL] [Abstract][Full Text] [Related]
18. [Multimodal therapy for colon cancer: state of the art].
Weber T; Link KH
Zentralbl Chir; 2011 Aug; 136(4):325-33. PubMed ID: 21863510
[TBL] [Abstract][Full Text] [Related]
19. Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.
Oh SY; Kim DY; Kim YB; Suh KW
World J Surg; 2013 Oct; 37(10):2497-503. PubMed ID: 23754140
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
